On Track to Profitability, Price Target Increased (MST), page-118

Glaucoma effects the elderly more as does arthritis, eye drop bottles are small, it can be difficult to put eye drops in your eye at the best of times and causes irritation for some people.

There are plenty of rich elderly and if they are already going to have a cataract done, then the discussion about crossing the threshold to do an invasive procedure is done.

This is like early days of cardiac stents, or percutaneous valves, gets easier to do, more people have it done, then patients who see benefit from the procedures become marketers. Glaucoma maybe not so much as patients don't feel anything unless IOP is quite high and the concept of measuring eye pressure is not so prevalent in general public health literature as measuring blood pressure.

iTrack is should be an easier sell to patients and to HCPs as you are fracking the channels to improve the flow so should be causing less damage than just ripping out the eye architecture like goniotomy or making a bypass channel with the stents that can blocked. RCT evidence is expensive and its less risky doing this vs drops but doing it vs other devices can end up showing you are actually worse like pravastatin vs atorvastatin.

Some HCPs might argue though without the destructive aspect it won't be as efficacious and that there is not much downside with the destructive components, all depends on how you pitch things.